hotspot -WSS

hotspot

author：comprehensive 2025-09-30 17:45:45 - browse：2

Obesity conference attendees with a pink and blue Wegovy sign hanging from the ceiling above. -- obesity coverage from STAT — Wegovy, the obesity drug, was inescapable at the ObesityWeek conference in Dallas. Elaine Chen

DALLAS — Here at ObesityWeek, one of the largest conferences on obesity, Novo Nordisk and Eli Lilly are displaying more than a dozen studies that together carry the message: Our blockbuster weight loss treatments will be worth it for society.

But experts point out that much of this company-funded research does not include the cost of the drugs themselves, which sell at more than $10,000 per year in the U.S. and are meant to be taken indefinitely.

The two major pharmaceutical companies have seen interest skyrocket for their GLP-1-based drugs like Ozempic, Wegovy, and Mounjaro, a new generation of medications that can cut substantial amounts of weight. But insurance plans have been slow to grant wide access to obesity treatments, concerned that the vast amount of people eligible to take them, along with their high price, could lead to significant financial strain.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： FDA drug safety: Singulair case shows systemic surveillance flaws

WSS

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

What we need to know about Arena Bioworks

UCB departs biotech trade group BIO

Covid misinformation case heads to Supreme Court

General Catalyst, Summa Health deal will turn on physician buy

hotspot

hotspot

focus

Moonlake's readout produced a cash windfall. Risks remain

Feng Zhang CRISPR delivery startup lays off quarter of staff

Cancer drug shortages should be causing more outrage

Quicker fix for pulse oximeters urged during FDA public meeting

Drug repurposing or repositioning? The language matters

The FDA must approve intranasal treatments for anaphylaxis

Medical leaders decry Supreme Court decision on affirmative action

Feng Zhang, Grail founder join forces on new gene editing startup

BioMarin wins approval for gene therapy to treat hemophilia A

Burning questions for the 2024 JPM Healthcare Conference

leisure time

Federal weight loss drug coverage is 30 years out of date

White House finalizes ITC's import ban of latest Apple Watches

3 medical device trends to watch in 2024

Feng Zhang CRISPR delivery startup lays off quarter of staff

Apple Vision Pro: A first look at health apps on the new VR headset

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

entertainment

focus

focus

explore